Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Psychopharmacology

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0269881107077357PMID 17715206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6

  2007cited by this paper
• The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.

  2006cited by this paper
• Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

  2005cited by this paper
• Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6

  2005cited by this paper
• Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia

  2003cited by this paper
• Effects of Various CYP2D6 Genotypes on the Steady-State Plasma Concentrations of Risperidone and Its Active Metabolite, 9-Hydroxyrisperidone, in Japanese Patients With Schizophrenia

  2003cited by this paper
• Plasma Concentration of Risperidone Showed a Correlation with Daily Dose, but not with Age nor Cytochrome P‐450 2D6 Gene Polymorphisms in Japanese Schizophrenics

  2002cited by this paper
• Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia.

  2002cited by this paper
• Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

  2001cited by this paper
• Molecular basis of ethnic differences in drug disposition and response.

  2001cited by this paper
• Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.

  2001cited by this paper
• Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

  2001cited by this paper
• Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

  2000cited by this paper
• The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

  2000cited by this paper
• Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.

  2000cited by this paper
• Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore--a preliminary report.

  1999cited by this paper
• Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone

  1999cited by this paper
• Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore--a preliminary report.

  1999cited by this paper
• Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

  1999influential reference
• Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

  1999cited by this paper
• Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.

  1998cited by this paper
• Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

  1998cited by this paper
• Serum concentrations and side effects in psychiatric patients during risperidone therapy.

  1998cited by this paper
• Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs.

  1997cited by this paper
• Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

  1996cited by this paper
• Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat

  1994cited by this paper
• Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.

  1994cited by this paper
• Clinical review of risperidone.

  1993cited by this paper
• Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

  1993cited by this paper
• Serum prolactin as a correlate of clinical response to haloperidol.

  1991cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• Biochemical profile of risperidone, a new antipsychotic.

  1988cited by this paper
• Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response.

  1983cited by this paper
• The Brief Psychiatric Rating Scale for Children.

  1982cited by this paper

• Influence of Genetic Variants on Risperidone-Associated Prolactin Elevation in Thai Pediatric ASD Patients

  2025cites this paper
• Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

  2023cites this paper
• Plasma Concentration of Risperidone: Correlation with Clinical Response in Patients with Schizophrenia

  2021cites this paper
• Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity.

  2021cites this paper
• Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder

  2021cites this paper
• Relation between plasma concentration of Risperidone and its efficacy in patients with schizophrenia: A review article

  2021cites this paper
• The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis

  2020cites this paper
• CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta‐analysis

  2020cites this paper
• Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia

  2019cites this paper
• Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

  2018influential citation
• Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application

  2018cites this paper
• A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia

  2018cites this paper
• Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants.

  2018cites this paper
• Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients

  2017cites this paper
• Assessment of Prolactin Level Among Sudanese Psychiatric Subjects

  2017cites this paper
• Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns

  2017cites this paper
• Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells

  2017cites this paper
• CYP2D6 polymorphisms and their influence on risperidone treatment

  2016cites this paper
• Pharmacokinetic patterns of risperidone-associated adverse drug reactions

  2016cites this paper
• Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.

  2016cites this paper
• Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting.

  2016cites this paper
• Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs

  2015cites this paper
• Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort

  2015cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial.

  2014cites this paper
• Prolactin and Psychopathology in Schizophrenia: A Literature Review and Reappraisal

  2014cites this paper
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cites this paper
• Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation

  2013cites this paper
• Pharmacogenomics can improve antipsychotic treatment in schizophrenia

  2013cites this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cites this paper
• Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature.

  2013cites this paper
• Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers.

  2012cites this paper
• Genetic Polymorphisms in CYP2E1: Association with Schizophrenia Susceptibility and Risperidone Response in the Chinese Han Population

  2012cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Converging evidence of blood-based biomarkers for schizophrenia: an update.

  2011cites this paper
• Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses

  2011cites this paper
• DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers

  2011cites this paper
• The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

  2010cites this paper
• A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.

  2010cites this paper
• Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.

  2010cites this paper
• Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers

  2010cites this paper
• Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients

  2010cites this paper
• HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients.

  2010cites this paper
• Etude des facteurs cliniques et pharmacogénétiques prédictifs de la réponse (efficacité) aux traitements neuroleptiques atypiques dans la schizophrénie

  2009cites this paper
• Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

  2009cites this paper
• Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response

  2009cites this paper
• Current awareness in human psychopharmacology.

  2008cites this paper
• The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.

  2008cites this paper
• [Pharmacogenetics of antipsychotics in schizophrenia].

  2008cites this paper
• Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder.

  2008cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• Restless Legs Syndrome Caused by Quetiapine Successfully Treated With Ropinirole in 2 Patients With Bipolar Disorder

  2008cites this paper
• Osteoporosis after combined use of a neuroleptic and antidepressants

  2008cites this paper
• Deconstructing a Medication Regimen

  2008cites this paper
• Clinical Manual of Drug Interaction Principles for Medical Practice

  2008cites this paper
• Paliperidone for schizophrenia.

  2007cites this paper